Medical Oncology

, Volume 28, Issue 3, pp 796–803

Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)

  • Yu Yang
  • Jiang Zhu
  • Hongfeng Gou
  • Dan Cao
  • Ming Jiang
  • Mei Hou
Original Paper

Abstract

Cox-2, Survivin and Bcl-2 are frequently overexpressed in numerous types of cancers. They are known to be the important regulators of apoptosis. This study was designed to investigate the correlation between the clinical characteristics and the expression of Cox-2, Survivin and Bcl-2 in hepatocellular carcinoma. A total of 63 postoperative hepatocellular carcinoma (HCC) samples, 10 adjacent non-tumor samples and 10 normal liver samples were immunochemically detected for the expression of Cox-2, Survivin and Bcl-2. A median follow-up of 4 years for the 63 HCC patients was conducted. Univariate tests and multivariate Cox regression were performed for statistical analysis. The Kaplan–Meier method was used to analyze the survival. Positive expression of Cox-2 (84.3%) and Survivin (77.8%) was detected significantly more frequently in the HCC samples than in the normal liver tissues (30% and 0, respectively). Bcl-2 was highly expressed in the adjacent non-tumor tissue. Cox-2 was positively correlative to Survivin. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC (P < 0.05). Expression of both Cox-2 and Survivin was significantly associated with the poor overall survival (OS) (P = 0.0141, P = 0.0039). Furthermore, multivariate analysis confirmed the independent prognostic value of Survivin expression, along with tumor size and hepatic function. Cox-2 and Survivin were highly expressed in the HCC tissue. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC. The expression of Survivin was an independent prognostic factor for HCC after a hepatectomy. Treatment that inhibits Survivin may be a promising targeted approach in HCC.

Keywords

Cox-2 Survivin Bcl-2 Hepatocellular carcinoma 

References

  1. 1.
    Bruix J, Sherman M, Llovet J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35(3):421–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Kelley RK, Alan P. Venook. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008;26:5845–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Koki AT, Masferer JL. Celecoxib: a specific Cox-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2Suppl):28–35.PubMedGoogle Scholar
  7. 7.
    Santini D, Vincenzi B, Tonini G et al. Cyclooxygenase -2 overexpression is associated with a poor outcome in resected ampullary cancer patients. Clin Cancer Res. 2005;11(10):3784–9.Google Scholar
  8. 8.
    Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421–6.PubMedGoogle Scholar
  9. 9.
    Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001;7:861–7.PubMedGoogle Scholar
  10. 10.
    Ferrandina G, Ranelletti FO, Legge F, et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clin Cancer Res. 2004;10:3117–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Raspollini MR, Amunni G, Villanucci A, et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol. 2004;92:806–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawasaki H, Toyoda M, Shinohara H, et al. Expression of Survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Salz W, Eisenberg D, Plescia J, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65:3531–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 2002;21:315–20.PubMedGoogle Scholar
  15. 15.
    Caldas H, Jaynes FO, Boyer MW, et al. Survivin and granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther. 2006;5:693–703.PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597–604.PubMedCrossRefGoogle Scholar
  17. 17.
    Reed JC, Miyashita T, Takayama S, et al. Bcl-2 proteins: relators of cell death in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60(1):23–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Martínez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res. 2007;27:219–22.PubMedGoogle Scholar
  19. 19.
    Leahy DT, Mulcahy HE, O‘Donoghue DP, et al. Bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology. 1999;35(4):360–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of Cox-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204:241–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Barnes N, Haywood P, Flint P, et al. Survivin expression in in situ and invasive breast cancer relates to Cox-2 expression and DCIS recurrence. Br J Cancer. 2006;94:253–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Krysan K, Merchant FH, Zhu L, et al. Cox-2-dependent stabilization of Survivin in non-small cell lung cancer. FASEB J. 2004;18:206–8.PubMedGoogle Scholar
  23. 23.
    Lu CD, AltieriD C, Tanigawa N, et al. Expression of a novel Antiapoptosis gene, Survivin, correlated with tumor cell apoptosis and p53 accumulationin gastric carcinomas. Cancer Res. 1998;58(9):1808–12.PubMedGoogle Scholar
  24. 24.
    Wang M, Wang B, Wang X. A novel antiapoptosis gene, survivin, Bcl-2, p53 expression in cervical carcinomas. Zhonghua Fu Chan KeZaZhi. 2001;36(9):54–68.Google Scholar
  25. 25.
    Sheng HM, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58(2):362–6.PubMedGoogle Scholar
  26. 26.
    Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxy genase-2 inhibitor, induces apoptosis and down-regulates Bcl-2 expression in LNCaP cells. Cancer Res. 1998;58(19):4245–9.PubMedGoogle Scholar
  27. 27.
    Cheng J, Imanishi H, Iijima H, et al. Expression of cyclooxygenase- 2 and cytosoli phospholipase A2 in the liver tissue of patients with chroni-chepatitis and liver cirrhosis. Hepatol Res. 2002;23(3):185–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma : relevance to tumor dedifferentiation. Hepatology. 1999;29:688–96.PubMedCrossRefGoogle Scholar
  29. 29.
    Bae SH, Jung ES, Park YM, et al. Expression of cyclooxigenase-2 (Cox-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a Cox-2 inhibitor, NS-398. Clin Cancer Res. 2001;7:1410–8.PubMedGoogle Scholar
  30. 30.
    Kondo M, Yamamoto H, Nagano H, et al. Increased expression of Cox-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999;5:4005–12.PubMedGoogle Scholar
  31. 31.
    Tang TC, Poon RT, Lau CP, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol. 2005;11(13):1896–902.PubMedGoogle Scholar
  32. 32.
    Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol. 2009;62:690–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Gianani R, Jarboe E, Orlicky D, et al. Expression of Survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32(1):119–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Grossman D, McNiff JM, Li F, et al. Expression of the apoptosis inhibitor, Survivin, in non melanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79(9):1121–6.PubMedGoogle Scholar
  35. 35.
    Weikert S, Christoph F, Schrader M, et al. Quantitative analysis of Survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;116(1):100.PubMedCrossRefGoogle Scholar
  36. 36.
    Osman HG, Gabr OM, Lotfy S, et al. Serum levels of Bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J Med Microbiol. 2007;25:323–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Wu T, Leng J, Han C, et al. The cyclooxygenase inhibitor celecoxib block sphosphory lationos Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3(3):299–307.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Yu Yang
    • 1
  • Jiang Zhu
    • 1
    • 2
  • Hongfeng Gou
    • 1
  • Dan Cao
    • 1
  • Ming Jiang
    • 1
  • Mei Hou
    • 1
    • 2
  1. 1.Department of Medical Oncology, Cancer Center of West China HospitalSichuan UniversityChengduChina
  2. 2.Department of Thoracic Oncology, Cancer Center of West China HospitalSichuan UniversityChengduChina

Personalised recommendations